Cover Image

Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Show other versions (1)

Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim o...

Full description

Saved in:
Bibliographic Details
Main Authors: Eichhorn, Florian (Author) , Klotz, Laura Valentina (Author) , Bischoff, Helge (Author) , Thomas, Michael (Author) , Lasitschka, Felix (Author) , Winter, Hauke (Author) , Hoffmann, Hans (Author) , Eichhorn, Martin E. (Author)
Format: Article (Journal)
Language:English
Published: 02 May 2019
In: BMC cancer
Year: 2019, Volume: 19
ISSN:1471-2407
DOI:10.1186/s12885-019-5624-2
Online Access:Verlag, Volltext: https://doi.org/10.1186/s12885-019-5624-2
Get full text
Author Notes:Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann and Martin E. Eichhorn
Description
Summary:Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017-000105-20; ClinicalTrials.govIdentifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival.
Item Description:Gesehen am 10.03.2020
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-019-5624-2

Similar Items